[1]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130-1133.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
 CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(8):1130-1133.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
点击复制

瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年8期
页码:
1130-1133
栏目:
出版日期:
2019-11-25

文章信息/Info

Title:
Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease
作者:
陈元1 楚天舒2 武力勇2
(1.昆明医科大学研究生院,云南 昆明 650000;2.昆明医科大学第二附属医院心血管内科,云南 昆明 650000)
Author(s):
CHEN Yuan1CHU Tianshu2WU Liyong2
(1.Kunming Medical University Graduate School, Kunming 650000, Yunnan, China 2.Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan, China)
关键词:
冠状动脉粥样硬化性心脏病瘦素瘦素受体瘦素抵抗基因多态性
Keywords:
Coronary atherosclerotic heart disease Leptin Leptin receptor Leptin resistance Gene polymorphism
DOI:
10.16806/j.cnki.issn.1004-3934.2019.08.015
摘要:
冠状动脉粥样硬化性心脏病(冠心病)是致残致死率很高的疾病之一,近年来有关冠心病与瘦素之间关系的研究越来越多。尤其在肥胖个体中,瘦素抵抗现象与冠心病的发生存在密切联系。目前认为瘦素受体的基因多态性可能在瘦素抵抗现象中发挥重要作用。现对有关文献进行整理并总结了瘦素抵抗、瘦素受体基因多态性与冠心病发病相关研究进展,为冠心病的防治提供一定参考。
Abstract:
Coronary atherosclerotic heart disease is one of the diseases with high disability and mortality. In recent years, more and more studies have been conducted on the relationship between coronary atherosclerotic heart disease and leptin. Especially in obese individuals, leptin resistance are closely related to the occurrence of coronary atherosclerotic heart disease. It is believed that the gene polymorphism of leptin receptor may play an important role in leptin resistance. This paper summarizes the research progress of leptin resistance,leptin receptor gene polymorphism and the incidence of coronary atherosclerotic heart disease,and provides some reference for the prevention and treatment of coronary atherosclerotic heart disease

参考文献/References:

[1] Mechanick JI,Zhao S,Garvey WT. Leptin,an adipokine with central importance in the global obesity problem[J]. Glob Heart,2018,13(2):113-127.

[2] Jiang B,Liu Y,Liu Y,et al. Association of four insulin resistance genes with type 2 diabetes mellitus and hypertension in the Chinese Han population[J]. Mol Biol Rep,2014,41(2):925-933.

[3] Schaab M,Kratzsch J. The soluble leptin receptor[J]. Best Pract Res Clin Endocrinol Metab,2015,29(5):661-670.

[4] Sun Q,Cornelis MC,Kraft P,et al. Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels[J]. Hum Mol Genet,2010,19(9):1846-1855.

[5] Puurunen VP,Kiviniemi A,Lepoj?rvi S,et al. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease[J]. Ann Med,2017,49(5):448-454.

[6] Tsai JP,Wang JH,Chen ML,et al. Association of serum leptin levels with central arterial stiffness in coronary artery disease patients[J]. BMC Cardiovasc Disord,2016,16:80.

[7] Katsiki N,Mikhailidis DP,Banach M. Leptin,cardiovascular diseases and type 2 diabetes mellitus[J]. Acta Pharmacol Sin,2018,39(7):1176-1188.

[8] Yang R,Barouch LA. Leptin signaling and obesity:cardiovascular consequences[J]. Circ Res,2007,101(6):545-559.

[9] Drosos I,Chalikias G,Pavlaki M,et al. Differences between perivascular adipose tissue surrounding the heart and the internal mammary artery:possible role for the leptin-inflammation-fibrosis-hypoxia axis[J]. Clin Res Cardiol,2016,105(11):887-900.

[10] Bodary PF,Shen Y,Ohman M,et al. Leptin regulates neointima formation after arterial injury through mechanisms independent of blood pressure and the leptin receptor/STAT3 signaling pathways involved in energy balance[J]. Arterioscler Thromb Vasc Biol,2007,27(1):70-76.

[11] Recio-Mayoral A,Rimoldi OE,Camici PG,et al. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease[J]. JACC Cardiovasc Imaging,2013,6(6):660-667.

[12] Akboga MK,Canpolat U,Balci KG,et al.Increased platelet to lymphocyte ratio is related to slow coronary flow[J]. Angiology,2016,67(1):21-26.

[13] de Rosa S,Cirillo P,Pacileo M,et al. Leptin stimulated C-reactive protein production by human coronary artery endothelial cells[J]. J Vasc Res,2009,46(6):609-617.

[14] Gamez-Mendez AM,Vargas-Robles H,Ríos A,et al. Oxidative stress-dependent coronary endothelial dysfunction in obese mice[J]. PLoS One,2015,10(9):e0138609.

[15] Allison MA,Jenny NS,McClelland RL,et al. The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system:the multi-ethnic study of atherosclerosis[J]. J Hum Hypertens,2015,29(2):127-133.

[16] Bakirdogen S,Eren N,Bek SG,et al. The effects of serum leptin levels on thrombocyte aggregation in peritoneal dialysis patients[J]. Pak J Med Sci,2016,32(6):1464-1467.

[17] Vilahur G,Ben-Aicha S,Badimon L. New insights into the role of adipose tissue in thrombosis[J]. Cardiovasc Res,2017,113(9):1046-1054.

[18] Mansor LS,Mehta K,Aksentijevic D,et al. Increased oxidative metabolism following hypoxia in the type 2 diabetic heart,despite normal hypoxia signalling and metabolic adaptation[J]. J Physiol,2016,594(2):307-320.

[19] Matsuoka N,Ogawa Y,Hosoda1 K,et al. Human leptin receptor gene in obese Japanese subjects:evidence against either obesity-causing mutations or association of sequence variants with obesity[J]. Diabetologia,1997,40(10):1204-1210.

[20] Nowzari Z,Masoumi M,Nazari-Robati M,et al. Association of polymorphisms of leptin,leptin receptor and apelin receptor genes with susceptibility to coronary artery disease and hypertension[J]. Life Sci,2018,207:166-171.

[21] Kain D,Simon AJ,Greenberg A,et al. Cardiac leptin overexpression in the context of acute MI and reperfusion potentiates myocardial remodeling and left ventricular dysfunction[J]. PLoS One,2018,13(10):e0203902.

[22] Boumaiza I,Omezzine A,Rejeb J,et al. Relationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers[J]. Genet Test Mol Biomarkers,2012,16(7):726-733.

[23] Lian Y,Tang Z,Xie Y,et al Leptin receptor gene polymorphisms and risk of hypertension:a meta-analysis[J]. Int J Clin Exp Med,2015,8(8):14277-14282.

[24] Sun YM,Wang LF,Li J,et al. The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease[J]. Eur J Clin Pharmacol,2009,65(2):157-161.

[25] Khaki-Khatibi F,Mansouri F,Hajahmadipoorrafsanjani M,et al. Study of rs1137101 polymorphism of leptin receptor gene with serum levels of selenium and copper in the patients of non-ST-segment elevation myocardial infarction (NSTEMI) in an Iranian population[J]. Clin Biochem,2018,60:64-70.

[26] Li XL,Sui JQ,Lu LL,et al. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease:a concise review[J]. Lipids Health Dis,2016,15:53.

[27] Okada T,Ohzeki T,Nakagawa Y,et al. Impact of leptin and leptin-receptor gene polymorphisms on serum lipids in Japanese obese children[J]. Acta Paediatr ,2010,99(8):1213-1217.

[28] Furusawa T,Naka I,Yamauchi T,et al. The Q223R polymorphism in LEPR is associated with obesity in pacific islanders[J]. Hum Genet,2010,127(3):287-294.

[29] Yang MM,Wang J,Fan JJ,et al. Variations in the obesity gene "LEPR" contribute to risk of type 2 diabetes mellitus:evidence from a meta-analysis[J]. J Diabetes Res,2016,2016:5412084.

[30] Saukko M,Kes?niemi YA,Ukkola O. Leptin receptor Lys109Arg and Gln223Arg polymorphisms are associated with early atherosclerosis[J]. Metab Syndr Relat Disord,2010,8(5):425-430.

[31] Wu L,Sun D. Leptin receptor gene polymorphism and the risk of cardiovascular disease:a systemic review and meta-analysis[J]. Int J Environ Res Public Health,2017,14(4).

[32] ?ij?l? M,Santaniemi M,Bloigu R,et al. Leptin receptor Arg109 homozygotes display decreased total mortality as well as lower incidence of cardiovascular disease and related death[J]. Gene,2014,534(1):88-92.

[33] Wauman J,Tavernier J. Leptin receptor signaling:pathways to leptin resistance[J]. Front Biosci (Landmark Ed),2011,16:2771-2793.

[34] Elliott P,Chambers JC,Zhang W,et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease[J]. JAMA,2009,302(1):37-48.

[35] Xiao P,Shi J,Liu X. Associations of leptin and leptin receptor genetic variants with coronary artery disease:a meta-analysis[J]. Biosci Rep,2019,39(6).pii: BSR20190466.

相似文献/References:

[1]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
 ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(8):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
[2]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
 SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(8):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[3]孙涛 左权 周辉 刘安康 梁诚 汤圣兴.末梢桡动脉和无鞘技术在冠状动脉介入治疗中的应用现状[J].心血管病学进展,2020,(5):456.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.005]
[4]奚云萍 臧雁翔 李为民.临床SYNTAX计分及其衍生计分在冠心病血运重建预后中的应用价值[J].心血管病学进展,2020,(5):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
 XI Yunping,ZANG Yanxiang,LI Weimin.Value of Clinical SYNTAX Score and Its Derivative Score in Prognosis of Coronary Artery Disease with Revascularization[J].Advances in Cardiovascular Diseases,2020,(8):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
[5]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
 XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(8):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[6]史云聪,王立立 郭艺芳.维生素D与心血管疾病相关性研究进展[J].心血管病学进展,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
 SHI YuncongWANG LiliGUO Yifang.Vitamin D And Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
[7]李英  刘兴鹏.常见心血管病服药依从性[J].心血管病学进展,2020,(10):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
 LI Ying,LIU Xingpeng.Medication Adherence For Common Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(8):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
[8]肖亚楠 高传玉.经皮冠脉介入术后短程双联抗血小板治疗的研究进展[J].心血管病学进展,2021,(4):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
 XIAO Yanan,GAO Chuanyu.Short-term Dual Antiplatelet Therapy after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2021,(8):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
[9]吉蓉 寿锡凌.秋水仙碱在冠状动脉粥样硬化性心脏病防治中的研究进展与争议[J].心血管病学进展,2022,(1):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
 JI Rong,SHOU Xiling.Research Progress and Controversy of Colchicine in Prevention and Treatment of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(8):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
[10]赵攀果 黄毅雄 肖丽苹 李田昌.基于声学理论检测冠心病的新方法[J].心血管病学进展,2022,(12):1068.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.003]
 ZHAO PanguoHUANG YixiongXIAO LipingLI Tianchang.A New Method for the Diagnosis of Coronary Artery Disease Based on Acoustic Theory[J].Advances in Cardiovascular Diseases,2022,(8):1068.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.003]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81860092)
更新日期/Last Update: 2020-01-20